Company intelligence / Profile preview
Neuro3 Therapeutics
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Neuro3 recently licensed from Lundbeck two clinical-stage and one preclinical KCNQ2 activator programs and is responsible for development through clinical proof-of-concept in epilepsy and other CNS diseases; detailed clinical results have not yet been disclosed.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeRNA therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lundbeck (exclusive worldwide license and option agreement for KCNQ2 activators, with options for co-development, co-commercialization, and territory-specific licenses)
Beyond the preview
Go deeper on Neuro3 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuro3 Therapeutics.